首站-论文投稿智能助手
典型文献
Bile acids and sphingolipids in non-alcoholic fatty liver disease
文献摘要:
Non-alcoholic fatty liver disease (NAFLD) is one of the fastest-growing diseases, and its global prevalence is estimated to increase >50% by 2030. NAFLD is comorbid with metabolic syndrome, obesity, type 2 diabetes, and insulin resistance. Despite extensive research efforts, there are no pharmacologic or biological therapeutics for the treatment of NAFLD. Bile acids and sphingolipids are well-characterized signaling molecules. Over the last few decades, researchers have uncovered potential mechanisms by which bile acids and sphingolipids regulate hepatic lipid metabolism. Dysregulation of bile acid and sphingolipid metabolism has been linked to steatosis, inflammation, and fibrosis in patients with NAFLD. This clinical observation has been recapitulated in animal models, which are well-accepted by experts in the hepatology field. Recent transcriptomic and lipidomic studies also show that sphingolipids are important players in the pathogenesis of NAFLD. Moreover, the identification of bile acids as activators of sphingolipid-mediated signaling pathways established a novel theory for bile acid and sphingolipid biology. In this review, we summarize the recent advances in the understanding of bile acid and sphingolipid-mediated signaling pathways as potential contributors to NAFLD. A better understanding of the pathologic effects mediated by bile acids and sphingolipids will facilitate the development of new diagnostic and therapeutic strategies for NAFLD.
文献关键词:
Bile acids;Sphingolipids;Non-alcoholic fatty liver disease;Non-alcoholic steatohepatitis
作者姓名:
Jackson Kaitlyn G.;Way Grayson W.;Zhou Huiping
作者机构:
Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA;Center for Clinical and Translational Research, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA;Central Virginia Veterans Healthcare System, Richmond, VA 23249, USA
引用格式:
[1]Jackson Kaitlyn G.;Way Grayson W.;Zhou Huiping-.Bile acids and sphingolipids in non-alcoholic fatty liver disease)[J].中华医学杂志(英文版),2022(10):1163-1171
A类:
hepatology,Sphingolipids
B类:
Bile,acids,sphingolipids,alcoholic,fatty,liver,Non,NAFLD,one,fastest,growing,diseases,its,global,prevalence,estimated,increase,by,comorbid,metabolic,syndrome,obesity,type,diabetes,insulin,resistance,Despite,extensive,efforts,there,are,pharmacologic,biological,therapeutics,treatment,well,characterized,signaling,molecules,Over,last,few,decades,researchers,have,uncovered,potential,mechanisms,which,bile,regulate,hepatic,metabolism,Dysregulation,has,been,linked,steatosis,inflammation,fibrosis,patients,This,clinical,observation,recapitulated,animal,models,accepted,experts,field,Recent,transcriptomic,lipidomic,studies,also,show,that,important,players,pathogenesis,Moreover,identification,activators,mediated,pathways,established,novel,theory,biology,In,this,review,summarize,recent,advances,understanding,contributors,better,pathologic,effects,will,facilitate,development,new,diagnostic,strategies,steatohepatitis
AB值:
0.539422
相似文献
Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway
Yi-kuan Wu;Zheng-nan Ren;Sheng-long Zhu;Yun-zhou Wu;Gang Wang;Hao Zhang;Wei Chen;Zhao He;Xian-long Ye;Qi-xiao Zhai-State Key Laboratory of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Medicine,Jiangnan University,Wuxi 214122,China;College of Life Science,Northeast Agricultural University,Harbin 150038,China;National Engineering Research Center for Functional Food,Jiangnan University,Wuxi 214122,China;Shandong Key Laboratory of Endocrinology and Lipid Metabolism,Jinan 250021,China;School of Medicine,Shandong University,Jinan 250012,China;Ganjiang Chinese Medicine Innovation Center,Nanchang 330000,China
Transcription factor Klf9 controls bile acid reabsorption and enterohepatic circulation in mice via promoting intestinal Asbt expression
Shuang Liu;Man Liu;Meng-lin Zhang;Cui-zhe Wang;Yin-liang Zhang;Yu-jie Zhang;Chun-yuan Du;Su-fang Sheng;Wei Wang;Ya-tong Fan;Jia-ni Song;Jin-can Huang;Yue-yao Feng;Wei Qiao;Jin-long Huang;Yu-hui Li;Lu Zhou;Jun Zhang;Yong-sheng Chang-Key Laboratory of Immune Microenvironment and Disease(Ministry of Education),Tianjin Key Laboratory of Cellular Homeostasis and Disease,Department of Physiology and Pathophysiology,Tianjin Medical University,Tianjin 300052,China;Department of Basic Medicine,Shihezi University School of Medicine,Shihezi 832000,China;Key Laboratory of Biotechnology of Hubei Province,Key Laboratory of Biotechnology of Chinese Traditional Medicine,National&Local Joint Engineering Research Center of High-throughput Drug Screening Technology,Hubei University,Wuhan 430062,China;Department of Gastroenterology and Hepatology,Tianjin Medical University General Hospital,Tianjin 300052,China
Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells
Hao Shen;Han Yu;Qian-yu Li;Ya-ting Wei;Jing Fu;Hui Dong;Dan Cao;Lin-na Guo;Lei Chen;Yuan Yang;Ying Xu;Meng-chao Wu;Hong-yang Wang;Yao Chen-International Cooperation Laboratory on Signal Transduction,National Center for Liver Cancer,Ministry of Education Key Laboratory on signaling Regulation and Targeting Therapy of Liver Cancer,Shanghai Key Laboratory of Hepato-biliary Tumor Biology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University/NAVAL Medical University,Shanghai 200433,China;Department of Pathology,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Metabolism and Integrative Biology,Fudan University,Shanghai 200438,China;Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。